C
Carlo B. Ramirez
Researcher at Thomas Jefferson University
Publications - 26
Citations - 946
Carlo B. Ramirez is an academic researcher from Thomas Jefferson University. The author has contributed to research in topics: Liver transplantation & Transplantation. The author has an hindex of 11, co-authored 25 publications receiving 900 citations. Previous affiliations of Carlo B. Ramirez include Thomas Jefferson University Hospital.
Papers
More filters
Journal Article
Report from the National Transplantation Pregnancy Registry (NTPR): outcomes of pregnancy after transplantation.
Lisa A. Coscia,Serban Constantinescu,Michael J. Moritz,Adam M. Frank,Carlo B. Ramirez,Warren R. Maley,Cataldo Doria,Carolyn H. McGrory,Vincent T. Armenti +8 more
TL;DR: Key benefits of the NTPR are the personal contact between registry staff and participants, the wide range of pregnancy-related variables that are analyzed, and the opportunity for health-care providers to obtain information that helps them care for transplant recipients on a case-by-case basis.
Journal ArticleDOI
The role of basiliximab induction therapy in organ transplantation
TL;DR: Basiliximab induction therapy given at days 0 and 4 after transplantation appears to be safe and cost-effective for immunoprophylaxis in solid organ transplant recipients, specifically in kidney and liver transplantation, when given in conjunction with dual or triple immunosuppressive therapy.
Journal ArticleDOI
The adipose tissue production of adiponectin is increased in end-stage renal disease.
Maria P. Martinez Cantarin,Scott A. Waldman,Cataldo Doria,Adam M. Frank,Warren R. Maley,Carlo B. Ramirez,Scott W. Keith,Bonita Falkner +7 more
TL;DR: It is suggested that adipose tissue production of adiponectin contributes to the high plasma levels seen in end stage renal disease.
Journal ArticleDOI
Anti-IL2 induction in liver transplantation with 93% rejection-free patient and graft survival at 18 months.
Carlo B. Ramirez,Cataldo Doria,Fabrizio di Francesco,Maurizio Iaria,Yoogoo Kang,Ignazio R. Marino +5 more
TL;DR: These preliminary data suggest that basiliximab, given in combination with a tacrolimus-based immunosuppressive regimen, is safe and associated with a low incidence of acute rejection and excellent short-term rejection-free graft and patient survival rate after OLT.
Journal ArticleDOI
Completely steroid-free immunosuppression in liver transplantation: a randomized study.
TL;DR: This study assesses the safety and efficacy of CS‐free immunosuppressive regimen in adult OLT.